Protalix BioTherapeutics awarded President and CEO Bashan Dror 480,000 derivative securities on 2026-09-03 at $0 per share. After the transactions, Dror owned 160,000 derivative securities. The figures give PLX investors the reported size of the award, its stated transaction price and the executive’s resulting derivative-securities position.

Key Highlights

  • The transactions were recorded at $0 per share on 3 September 2026.
  • Bashan Dror owned 160,000 derivative securities after the transactions.
  • Bashan Dror is Protalix BioTherapeutics’ president and CEO.

Protalix BioTherapeutics, Inc. (AMEX: PLX) awarded 480,000 derivative securities to Bashan Dror, its president and CEO. The transactions were dated 3 September 2026 and carried a stated price of $0 per share.

480,000 Derivative Securities Awarded The

award covered derivative securities across 2 separate transactions coded A. Bashan Dror was identified in the transaction record as Protalix BioTherapeutics’ president and CEO. The stated price for the securities was $0 per share. The award total was 480,000 derivative securities.

160,000 Securities Held After Transactions Dror

owned 160,000 derivative securities following the transactions. That figure represents the reported post-transaction holding associated with the executive.